Drugs Information Online
Drugs and diseases reference index

Drugs and diseases reference index

Drugs A-Z List

Diseases & Conditions A-Z List

Herbs & Supplements

Medical Dictionary

Full Article

Popular Drugs

Popular Diseases & Conditions

Drugs reference index «Benazepril Hydrochloride»

Benazepril Hydrochloride

Pronunciation: (BEN-AZE-uh-prill HIGH-droe-KLOR-ide)Class: ACE inhibitor

Trade Names:Lotensin- Tablets 5 mg- Tablets 10 mg- Tablets 20 mg- Tablets 40 mg


Competitively inhibits angiotensin-converting enzyme (ACE), resulting in decreased conversion of angiotensin I to angiotensin II, a potent vasoconstrictor that stimulates aldosterone secretion. Results in decreased vasopressor activity and decreased aldosterone secretion.



T max is 0.5 to 1 h (benazepril), 1 to 2 h (benazeprilat) in fasting state, and 2 to 4 h (benazeprilat) in nonfasting state. Up to 37% absorbed.


Protein binding is about 96.7% (benazepril) and about 95.3% (benazeprilat).


Converted to benazeprilat (active) by cleavage of ester group (primarily in liver). Also metabolized to glucuronide conjugates.



Benazepril (trace amounts), benazeprilat (about 20%), benazepril glucuronide (4%), benazeprilat glucuronide (8%).

Nonrenal (eg, biliary)

About 11% to 12% (benazeprilat).


Within 1 h.


2 to 4 h.


24 h.

Special Populations

Renal Function Impairment

In those with Ccr up to 30 mL/min, peak benzaprilat levels and initial t ½ increase and time to steady state may be delayed.

Indications and Usage

Treatment of hypertension.


Hypersensitivity to ACE inhibitors.

Dosage and Administration

Adults Initial dose

PO 10 mg/day for patients not receiving a diuretic. In patients taking diuretics that cannot be discontinued, give initial dose of 5 mg. Administer without regard to meals or with food if GI upset occurs.


PO 20 to 40 mg/day as single dose or in 2 divided doses; doses up to 80 mg have been used.

Children (6 yr of age and older) Initial dose

PO 0.2 mg/kg/day.


PO 0.2 to 0.6 mg/kg as single dose; doses above 0.6 mg/kg (or more than 40 mg) have not been studied.

Renal function impairment

Initial dose is 5 mg/day for patients with Ccr less than 30 mL/min. Dosage may be titrated upward until BP is controlled or to a total max dose of 40 mg/day.

General Advice

For patient who cannot swallow tablets or whose calculated dose (mg/kg) does not correspond to available tablet size, use extemporaneous suspension as follows: to prepare 150 mL of 2 mg/mL suspension, add 75 mL Ora-Plus oral suspending vehicle to amber polyethylene terephthalate (PET) bottle containing 15 benazepril 20 mg tablets and shake for at least 2 min. Let stand for 1 h minimum then shake for minimum of 1 additional min, add 75 mL of Ora-Sweet oral syrup and shake to disperse ingredients.

Shake suspension before measuring dose. Measure and administer prescribed dose using dosing syringe, dosing spoon, or dosing cup.


Store tablets at or below 86°F. Protect from moisture. Store suspension in refrigerator (36° to 46°F). Discard any unused suspension after 30 days.

Drug Interactions


May decrease bioavailability of benazepril; separate administration by 1 to 2 h.


May cause symptomatic hypotension after initial dose of benazepril.


May increase lithium levels and symptoms of lithium toxicity.

Potassium preparations, potassium-sparing diuretics

May increase serum potassium levels.

Salicylates (eg, aspirin)

May reduce effects of benazepril, especially in low-renin or volume-dependent hypertensive patients.

Laboratory Test Interactions

None well documented.

Adverse Reactions


Angina pectoris, ECG changes, palpitations, peripheral edema, postural hypotension, symptomatic hypotension, syncope (postmarketing).


Headache (6%); dizziness (4%); fatigue, postural dizziness, somnolence (2%); anxiety, asthenia, decreased libido, hypertonia, insomnia, nervousness, paresthesia (postmarketing).


Alopecia, apparent hypersensitivity (dermatitis, pruritus, rash), flushing, pemphigus, photosensitivity, Stevens-Johnson syndrome, sweating (postmarketing).


Nausea (1%); constipation, gastritis, melena, pancreatitis, vomiting (postmarketing).


Impotence, increased BUN, increased serum creatinine, UTI (postmarketing).


Eosinophilia, hemolytic anemia, leukopenia, thrombocytopenia (postmarketing).

Lab Tests

Increased serum creatinine (2%); hyperkalemia, increased uric acid, increased blood glucose, increased serum bilirubin, increased liver enzymes (postmarketing).


Arthralgia, arthritis, myalgia (postmarketing).


Protein uria (postmarketing).


Chronic dry cough (1%); asthma, bronchitis, eosinophilic pneumonitis, sinusitis (postmarketing).


Anaphylactoid reactions; angioedema; fetal and neonatal morbidity and death, hyponatremia, infection (postmarketing).




When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing fetus. When pregnancy is detected, discontinue therapy as soon as possible.


Ensure serum electrolytes and renal function are monitored periodically. Monitor and record BP and pulse. Monitor WBC in patients with collagen-vascular disease.


Category D (second and third trimester); Category C (first trimester). When pregnancy is detected, discontinue ACE inhibitors as soon as possible.


Excreted in breast milk; avoid use in breast-feeding mothers if possible.


Not recommended in children younger than 6 yr of age or if glomerular filtration rate is less than 30 mL/min.


Consider lower starting dose and slower dose titration.

Renal Function

Reduce dose. Monitor renal function during first few weeks of therapy, when dose is increased, or during concurrent treatment with diuretic. Benazepril dose reduction or discontinuation of diuretic may be required if increases in Ccr and BUN occur.

Hazardous Tasks

May cause drowsiness, dizziness, or lightheadedness. Use with caution while driving or performing other tasks requiring mental alertness until tolerance is determined.


May occur.


May occur. Use with extreme caution in patients with hereditary angioedema. Angioedema of the tongue, glottis, or larynx may cause airway obstruction; consider use of subcutaneous epinephrine. Consider intestinal angioedema in differential diagnosis of patients on ACE inhibitor presenting with abdominal pain.

Concurrent diuretic use

If possible, discontinue diuretic therapy for 2 to 3 days prior to beginning benazepril therapy.


Persistent nonproductive cough, always resolving after discontinuation of therapy, has been reported with ACE inhibitors.

Fetal/Neonatal morbidity and mortality

May occur. Discontinue benazepril as soon as possible if patient becomes pregnant.

Hepatic failure

ACE inhibitors rarely have been associated with a syndrome that starts with cholestatic jaundice and progresses to fulminant hepatic necrosis and sometimes death.


Has been reported. Risk factors include renal function impairment, diabetes mellitus, and concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes.

Hypotension/First-dose effect

Significant decreases in BP may occur after first dose, especially in severely salt- or volume-depleted patients (eg, those undergoing dialysis or vigorous diuretic therapy) or those with heart failure. Risk is minimized by discontinuing use of diuretics, increasing salt intake about 1 wk before initiating benazepril, or decreasing benazepril dose.


Has occurred with other ACE inhibitors, most often in patients with renal function impairment and a collagen-vascular disease (eg, systemic lupus erythematosus).




Patient Information

  • Advise patient to take daily or twice daily as prescribed, without regard to meals but to take with food if stomach upset occurs.
  • Advise patient to try to take each dose at about the same time each day.
  • Inform patient that drug controls but not does cure hypertension and to continue taking drug as prescribed even when BP is not elevated.
  • Caution patient not to change the dose or stop taking unless advised by health care provider.
  • Instruct patient to continue taking other BP medications as prescribed by health care provider.
  • Instruct patient in BP and pulse measurement skills.
  • Advise patient to monitor and record BP and pulse at home and to inform health care provider if abnormal measurements are noted. Advise patient to take record of BP and pulse to each follow-up visit.
  • Caution patient to avoid sudden position changes to prevent orthostatic hypotension.
  • Instruct patient to lie or sit down if they experience dizziness or lightheadedness when standing.
  • Emphasize importance of the following other modalities on BP control: weight control, regular exercise, smoking cessation, moderate intake of alcohol and salt.
  • Caution patient that inadequate fluid intake, excessive perspiration, diarrhea, or vomiting can lead to excessive fall in BP, resulting in lightheadedness or fainting.
  • Advise patient that medication may cause dizziness or lightheadedness and to use caution while driving or performing other tasks requiring mental alertness until tolerance is determined.
  • Caution patient to avoid unnecessary exposure to UV light (sunlight, tanning booths) and to use sunscreen and wear protective clothing when exposed to UV light to avoid photosensitivity reaction.
  • Instruct patient to stop taking drug and immediately report any of the following symptoms to health care provider: sore throat; fever; swelling of the hands or feet; irregular heartbeat; chest pains; fainting; swelling of the face, lips, eyelids, or tongue; difficulty breathing; persistent abdominal pain.
  • Instruct patient to inform health care provider if they develop a persistent cough while taking this medication.

Copyright © 2009 Wolters Kluwer Health.

  • Benazepril Prescribing Information (FDA)
  • benazepril Advanced Consumer (Micromedex) - Includes Dosage Information
  • Benazepril MedFacts Consumer Leaflet (Wolters Kluwer)
  • Lotensin Prescribing Information (FDA)
  • Lotensin Detailed Consumer Information (PDR)
  • Lotensin Consumer Overview

Comment «Benazepril Hydrochloride»